How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Pulmonary Drug Delivery Devices Market
- By Device Type: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Soft Mist Inhalers (SMIs)
- By Therapeutic Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Arterial Hypertension, Respiratory Infections
- By End User: Hospitals, Home Care Settings, Clinics, Specialty Respiratory Centers
- By Propellant Type: Hydrofluoroalkane (HFA) Propellants, Chlorofluorocarbon (CFC) Propellants, Breath-Actuated Propellants
- By Technology: Breath-Actuated Inhalers, Smart Inhalers, Disposable Inhalers, Reusable Inhalers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Metered Dose Inhalers (MDIs) leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Pulmonary Drug Delivery Devices Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Device Type 4
Therapeutic Application 5
End User 4
Propellant Type 3
Technology 4
Companies profiled
AstraZeneca plc
GlaxoSmithKline plc
Boehringer Ingelheim GmbH
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now part of Viatris)
Novartis AG
Chiesi Farmaceutici S.p.A.
Becton
Dickinson and Company (BD)
Phillips-Medisize (a Molex company)
3M Company
Vyaire Medical Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Mylan N.V. (now part of Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Chiesi Farmaceutici S.p.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Phillips-Medisize (a Molex company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →3M Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Vyaire Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cipla Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sandoz International GmbH (a Novartis division)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Meda AB (acquired by Mylan)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$9,671M by 2033 · 10.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Metered Dose Inhalers (MDIs)57.5
- Dry Powder Inhalers (DPIs)9.7
- Nebulizers21.0
- Soft Mist Inhalers (SMIs)11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,466M → $3,394M · 11.1%
Europe$1,022M → $2,092M · 9.4%
Asia Pacific$932.9M → $2,066M · 10.4%
Latin America$577.5M → $1,259M · 10.2%
Middle East and Africa$444.3M → $915.6M · 9.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.172026
10.182027
10.182028
10.192029
10.222030
10.222031
10.242032
10.252033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- AstraZeneca plc11.9
- GlaxoSmithKline plc21.4
- Boehringer Ingelheim GmbH11.0
- Teva Pharmaceutical Industries Ltd.11.7
- Mylan N.V. (now part of Viatris)10.7
- Novartis AG5.2
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type25.2%
Therapeutic Application14.0%
End User11.6%
Propellant Type28.9%
Technology20.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe21.5
- Asia Pacific21.2
- Latin America12.9
- Middle East and Africa9.4
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| AstraZeneca plc | 82 | 95 | 74 | 96 | 98 | 83 | 88 |
| GlaxoSmithKline plc | 78 | 90 | 70 | 74 | 84 | 87 | 81 |
| Boehringer Ingelheim GmbH | 65 | 67 | 80 | 82 | 63 | 76 | 72 |
| Teva Pharmaceutical Industries Ltd. | 71 | 72 | 62 | 70 | 75 | 62 | 69 |
| Mylan N.V. (now part of Viatris) | 74 | 62 | 76 | 74 | 59 | 75 | 70 |
| Novartis AG | 53 | 59 | 66 | 61 | 68 | 54 | 60 |
| Chiesi Farmaceutici S.p.A. | 60 | 46 | 58 | 60 | 46 | 58 | 55 |
| Becton | 48 | 53 | 58 | 38 | 35 | 40 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- AstraZeneca plc
- GlaxoSmithKline plc
- Boehringer Ingelheim GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| AstraZeneca plc | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| GlaxoSmithKline plc | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Boehringer Ingelheim GmbH | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Teva Pharmaceutical Industries Ltd. | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Mylan N.V. (now part of Viatris) | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Novartis AG | − | − | ◐ | − | ◐ | ◐ |
| Chiesi Farmaceutici S.p.A. | ◐ | − | ◐ | − | − | ◐ |
| Becton | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1AstraZeneca plc88
2GlaxoSmithKline plc81
3Boehringer Ingelheim GmbH72
4Mylan N.V. (now part of Viatris)70
5Teva Pharmaceutical Industries Ltd.69
6Novartis AG60
7Chiesi Farmaceutici S.p.A.55
8Becton45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
AstraZeneca plcGlaxoSmithKline plc
Challenger3
Strong scale, closing on the leaders.
Boehringer Ingelheim GmbHTeva Pharmaceutical Industries Ltd.Mylan N.V. (now part of Viatris)
Contender1
Focused players with pockets of strength.
Novartis AG
Niche2
Specialists in a single segment or region.
Chiesi Farmaceutici S.p.A.Becton
Go-to-market strategy
Land Device Type in North America, then scale across Pulmonary Drug Delivery Devices Market — a $59M beachhead inside a $995M market.
Beachhead (SOM)$59Mobtainable near-term
Serviceable (SAM)$379Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Metered Dose Inhalers (MDIs)
Best fit — highest urgency & budget in Device Type.
Economic buyer80 fit
Dry Powder Inhalers (DPIs)
Strong fit — clear ROI and a fast path to value.
End user67 fit
Nebulizers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Pulmonary Drug Delivery Devices Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified26%
Evaluation14%
Closed-won7%
$15.7KCAC
$67KLTV
4.3:1LTV : CAC
< 4 moCAC payback
Investment thesis
Pulmonary Drug Delivery Devices Market is a durable-growth opportunity — $2.79B by 2033, compounding at 6.8%.
TAM · 2025$1.64Btoday
TAM · 2033$2.79Bforecast
CAGR6.8%2027–2033
Cumulative$19.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.79BTotal addressable market
SAM$1.02BServiceable available market
SOM$199MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.79BLarge & growingTAM by 2033 at 6.8% CAGR
$1.02BServiceable nowreachable with today’s model
$199MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.17BBear4.4% CAGR
$2.79BBase6.8% CAGR
$3.57BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Pulmonary Drug Delivery Devices Market — a $10.3B market by 2033. Plan: grow share from 8.9% to 16.9%.
Market size · 2033$10.3Btotal addressable
Market CAGR8.4%2027–2033
Target share16.9%from 8.9% today
Revenue ambition$1.75Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 16.9% | On track |
| Revenue | $920M | $1.75B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.9% | 40.5% | At risk |
| Customer retention | 85.3% | 92.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $256M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Sales deck · value proposition
Win the Pulmonary Drug Delivery Devices Market conversation — a $3.74B market you can size, segment and defend in minutes.
Market size · 2033$3.74Btotal opportunity
Growth5.4%CAGR to 2033
Addressable buyers1,012+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 4 mopayback period
$44K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
AstraZeneca plcGlaxoSmithKline plcBoehringer Ingelheim GmbHTeva Pharmaceutical Industries Ltd.Mylan N.V. (now part of Viatris)Novartis AGChiesi Farmaceutici S.p.A.Becton+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Pulmonary Drug Delivery Devices Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Pulmonary Drug Delivery Devices Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Medical Stapler Market
Market size, share, segmentation and regional forecast.
$11.3B by 2033 · 6.11% CAGR
View reportPDE Inhibitor Market
Market size, share, segmentation and regional forecast.
$5.9B by 2031 · 7.61% CAGR
View reportPhototherapy Equipments Market
Market size, share, segmentation and regional forecast.
$2.0B by 2032 · 4.07% CAGR
View reportPneumococcal Vaccines Market
Market size, share, segmentation and regional forecast.
$5.7B by 2033 · 9.14% CAGR
View reportOrthodontic Equipments Market
Market size, share, segmentation and regional forecast.
$8.1B by 2033 · 6.02% CAGR
View reportOrthopedic Trauma Device Market
Market size, share, segmentation and regional forecast.
$8.9B by 2031 · 3.27% CAGR
View reportOsteosynthesis External Fixation Devices Market
Market size, share, segmentation and regional forecast.
$4.1B by 2031 · 9.80% CAGR
View reportTreatment Patient Simulators Market
Market size, share, segmentation and regional forecast.
$5.8B by 2031 · 8.37% CAGR
View reportTangential Flow Filtration Device Market
Market size, share, segmentation and regional forecast.
$11.0B by 2031 · 9.61% CAGR
View reportTransfusion Diagnostic Equipments Market
Market size, share, segmentation and regional forecast.
$3.7B by 2033 · 5.77% CAGR
View reportPulmonary Arterial Hypertension Drugs Market
Market size, share, segmentation and regional forecast.
$3.6B by 2032 · 8.55% CAGR
View reportPulmonary Drugs Market
Market size, share, segmentation and regional forecast.
$3.0B by 2033 · 8.71% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.